肺癌立体定向放射治疗及其与免疫等综合治疗的临床与基础转化研究，重点关注放疗相关免疫代谢调控机制及干预策略

Primary research interests focus on stereotactic radiotherapy for lung cancer and its combination with immunotherapy and other systemic treatments, with an emphasis on the clinical and translational investigation of radiation-related immune-metabolic regulation and therapeutic intervention strategies.

中国医师协会肿瘤多学科诊疗专业委员会会员；中国临床肿瘤学会会员；上海市抗癌协会会员

Member, Tumor Multidisciplinary Treatment Professional Committee, Chinese Medical Doctor Association

Member, Chinese Society of Clinical Oncology (CSCO)

Member, Shanghai Anti-Cancer Association

刘娣，女，汉族，中共党员，上海市肺科医院放疗科主治医师，同济大学讲师、副研究员，同济大学医学博士，美国圣路易斯华盛顿大学联合培养医学博士。

主要业绩: 主持国家自然科学基金项目 1 项、白求恩中青年医师肿瘤研究基金项目 1 项，参与完成国家自然科学基金项目 2 项。以第一作者（含共同）在 Journal of Hematology & Oncology、MedComm、Cell Communication and Signaling、Respiratory Research 等期刊发表 SCI 论文 11 篇，合作发表 SCI 等学术论文 20 余篇。相关成果获第 33 届上海市优秀发明选拔赛金奖、同济大学 2020 年度“十大最具转化潜力科技成果”奖，并多次在世界肺癌大会（WCLC）、美国放射肿瘤学会（ASTRO）、美国临床肿瘤学会（ASCO）等国际学术会议作口头报告及壁报交流，授权国家专利 1 项。

·Serve as principal investigator for one NSFC project and one Bethune Young Oncologist Tumor Research Fund project, and have participated in two additional NSFC projects.

·As first or co-first author, have published 11 SCI papers in Journal of Hematology & Oncology, MedComm, Cell Communication and Signaling, Respiratory Research, etc., and co-authored over 30 additional SCI and other peer-reviewed articles.

· Work has been recognized with the Gold Award at the 33rd Shanghai Excellent Invention Selection Competition and the 2020 “Top Ten Most Translational Potential Scientific Achievements” Award of Tongji University, and has been presented multiple times at WCLC, ASTRO and ASCO metting.

·Hold one granted national patent and several other intellectual property outputs.